[go: up one dir, main page]

UY35993A - PROLINES / PIPERIDINS SUBSTITUTED AS ANTAGONISTS OF THE RECEIVER OF OREXINA - Google Patents

PROLINES / PIPERIDINS SUBSTITUTED AS ANTAGONISTS OF THE RECEIVER OF OREXINA

Info

Publication number
UY35993A
UY35993A UY0001035993A UY35993A UY35993A UY 35993 A UY35993 A UY 35993A UY 0001035993 A UY0001035993 A UY 0001035993A UY 35993 A UY35993 A UY 35993A UY 35993 A UY35993 A UY 35993A
Authority
UY
Uruguay
Prior art keywords
orexina
piperidins
prolines
antagonists
receiver
Prior art date
Application number
UY0001035993A
Other languages
Spanish (es)
Inventor
Theodore M Kamenecka
He Yuanjun
Nguyen William
Jiang Rong
William; Song Xinyi
Herr Robert Jason
Barnes Keith
Steven D Young
Jiang Qin
Original Assignee
Eolas Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/179,432 external-priority patent/US9499517B2/en
Priority claimed from US14/460,289 external-priority patent/US9440982B2/en
Application filed by Eolas Therapeutics Inc filed Critical Eolas Therapeutics Inc
Publication of UY35993A publication Critical patent/UY35993A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención hace referencia a compuestos que modulan la bioactividad de un receptor de orexina como por ejemplo OX1 o OX2, o ambos; a composiciones farmacéuticas y combinaciones que comprenden un compuesto de la invención; a métodos de tratamiento de afecciones en pacientes para las cuales se indica médicamente la modulación de un receptor de orexina; y a métodos de preparación de compuestos de la invención.The present invention refers to compounds that modulate the bioactivity of an orexin receptor such as OX1 or OX2, or both; to pharmaceutical compositions and combinations comprising a compound of the invention; to methods of treating conditions in patients for whom the modulation of an orexin receptor is medically indicated; and to methods of preparing compounds of the invention.

UY0001035993A 2014-02-12 2015-02-11 PROLINES / PIPERIDINS SUBSTITUTED AS ANTAGONISTS OF THE RECEIVER OF OREXINA UY35993A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/179,432 US9499517B2 (en) 2012-02-07 2014-02-12 Substituted prolines / piperidines as orexin receptor antagonists
US201462037471P 2014-08-14 2014-08-14
US14/460,289 US9440982B2 (en) 2012-02-07 2014-08-14 Substituted prolines/piperidines as orexin receptor antagonists

Publications (1)

Publication Number Publication Date
UY35993A true UY35993A (en) 2015-08-31

Family

ID=53800603

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035993A UY35993A (en) 2014-02-12 2015-02-11 PROLINES / PIPERIDINS SUBSTITUTED AS ANTAGONISTS OF THE RECEIVER OF OREXINA

Country Status (3)

Country Link
TW (1) TW201613891A (en)
UY (1) UY35993A (en)
WO (1) WO2015123355A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2491038T3 (en) 2009-10-23 2016-07-18 Janssen Pharmaceutica Nv Disubstituerede octahydropyrrolo [3,4-c]pyrroler som orexin receptormodulatorer
NZ628491A (en) 2012-02-07 2016-06-24 Eolas Therapeutics Inc Substituted prolines / piperidines as orexin receptor antagonists
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
TW201613902A (en) 2014-08-13 2016-04-16 Eolas Therapeutics Inc Difluoropyrrolidines as orexin receptor modulators
GB201601703D0 (en) * 2016-01-29 2016-03-16 C4X Discovery Ltd Therapeutic compounds
HRP20220906T1 (en) * 2016-02-12 2022-10-14 Astrazeneca Ab Halo-substituted piperidines as orexin receptor modulators
PL3426251T3 (en) 2016-03-10 2022-07-18 Janssen Pharmaceutica Nv Methods of treating depression using orexin-2 receptor antagonists
US20190142811A1 (en) * 2016-04-01 2019-05-16 Zeno Royalties & Milestones, LLC Estrogen receptor modulators
CN108239019B (en) * 2016-12-27 2021-05-04 浙江医药股份有限公司新昌制药厂 Synthesis method of (2S,5S or 5R) -N-tert-butyloxycarbonyl-5-hydroxy-2-ethyl piperidinecarboxylate
JP7182562B2 (en) * 2017-05-03 2022-12-02 イドーシア ファーマシューティカルズ リミテッド Preparation of 2-([1,2,3]triazol-2-yl)-benzoic acid derivatives
CN111138413B (en) * 2018-11-01 2022-11-04 江苏豪森药业集团有限公司 Preparation method of cyclin-dependent kinase inhibitor and intermediate thereof
WO2021234003A1 (en) * 2020-05-20 2021-11-25 F. Hoffmann-La Roche Ag Benzylpyridinium reagent for mass spectrometry
AR129309A1 (en) * 2022-05-13 2024-08-07 Idorsia Pharmaceuticals Ltd DERIVATIVES OF HYDRAZINE-N-CARBOXAMIDE CYCLIC SUBSTITUTED WITH THIAZOLOARYL-METHYL

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE344261T1 (en) * 2002-09-18 2006-11-15 Glaxo Group Ltd CYCLIC N-AROYLAMINS AS OREXIN RECEPTOR ANTAGONISTS
NZ628491A (en) * 2012-02-07 2016-06-24 Eolas Therapeutics Inc Substituted prolines / piperidines as orexin receptor antagonists
US9440982B2 (en) * 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists

Also Published As

Publication number Publication date
TW201613891A (en) 2016-04-16
WO2015123355A1 (en) 2015-08-20

Similar Documents

Publication Publication Date Title
UY35993A (en) PROLINES / PIPERIDINS SUBSTITUTED AS ANTAGONISTS OF THE RECEIVER OF OREXINA
CO2018006662A2 (en) Apeline receptor agonists and methods of use
NI201600144A (en) QUINOXALINE DERIVATIVES USEFUL AS MODULATORS OF FGFR KINASE
CL2018000150A1 (en) Useful compounds as immunomodulators (divisional application 201600508)
CL2017001204A1 (en) 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors
CL2018002505A1 (en) Wdr5 protein-protein aging inhibitors
CO2018002060A2 (en) Pharmaceutical compounds
GT201600215A (en) FUSIONED BICYCLIC HETEROARILO OR ARILO COMPOUNDS AND ITS USE AS IRAK4 INHIBITORS
UY37610A (en) ARILO HYDROCARBON RECEIVER MODULATING COMPOUNDS (AHR)
ECSP16061758A (en) GPR6 TETRAHYDROPYRIDOPYRAZINE MODULATORS
CU20170089A7 (en) QUINAZOLINE DERIVATIVES USED TO TREAT HIV
MX2013012896A (en) NEW COMPOUNDS AS PROTEIN KINASE MODULATORS.
UY36705A (en) 4-HYDROXI-3- (HETEROARIL) PIRIDIN-2-ONA COMPOUNDS AS APJ AGONISTS
CO2018007221A2 (en) Heteroarylhydroxypyrimidinones as apeline receptor agonists (apj)
DOP2015000157A (en) FUSIONED LACTAMAS OF ARILO AND HETEROARILO
CO2019007881A2 (en) Aryl hydrocarbon receptor (ahr) modulating compounds
CO2019007882A2 (en) Aryl hydrocarbon receptor (ahr) modulating compounds
CO2017002268A2 (en) Spirocyclic cathepsin c inhibitors
CU20190101A7 (en) SUBSTITUTED DIAZABICYCLIC IMIDAZOPYRIMIDINES
ECSP16078782A (en) ISOINDOLINONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS
BR112016018062A8 (en) therapeutic compounds, pharmaceutical composition and uses
GT201200004A (en) FUSIONATED IMIDAZOLS AND COMPOSITIONS THAT CONTAIN THEM FOR THE TREATMENT OF PARASITARY DISEASES, AS BY MALARIA EXAMPLE
ECSP17038999A (en) 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINES AS MODULATORS OF GPR139
DOP2016000212A (en) CONDENSED HETEROCICLES REPLACED AS MODULATORS OF GPR119 FOR THE TREATMENT OF DIABETES, OBESITY, DISLIPIDEMIA AND RELATED DISORDERS
UY35276A (en) New compounds that inhibit the activity of Lp-PLA2

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20220610